IQVIA (NYSE:IQV) Downgraded to “Hold” at StockNews.com

StockNews.com downgraded shares of IQVIA (NYSE:IQV) from a buy rating to a hold rating in a research report released on Friday.

IQV has been the subject of several other research reports. Robert W. Baird dropped their target price on shares of IQVIA from $254.00 to $245.00 and set a neutral rating for the company in a research report on Friday, May 3rd. Truist Financial cut their target price on IQVIA from $297.00 to $292.00 and set a buy rating on the stock in a research note on Friday, May 3rd. Evercore ISI decreased their target price on IQVIA from $275.00 to $250.00 and set an outperform rating for the company in a research report on Friday, May 3rd. SVB Leerink initiated coverage on shares of IQVIA in a research report on Monday, February 26th. They issued an outperform rating and a $290.00 price target on the stock. Finally, Leerink Partnrs reaffirmed an outperform rating on shares of IQVIA in a research note on Monday, February 26th. Four equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, IQVIA presently has a consensus rating of Moderate Buy and an average price target of $258.40.

IQVIA Trading Up 1.0 %

IQV stock opened at $216.25 on Friday. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. IQVIA has a twelve month low of $167.42 and a twelve month high of $261.73. The company has a market cap of $39.40 billion, a P/E ratio of 29.54, a PEG ratio of 1.94 and a beta of 1.53. The business has a fifty day moving average of $225.57 and a 200-day moving average of $230.17.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $2.30 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.11. The firm had revenue of $3.74 billion during the quarter, compared to analysts’ expectations of $3.69 billion. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. As a group, equities research analysts expect that IQVIA will post 10.11 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Kestra Advisory Services LLC grew its stake in shares of IQVIA by 39.1% during the 3rd quarter. Kestra Advisory Services LLC now owns 5,344 shares of the medical research company’s stock worth $1,051,000 after acquiring an additional 1,502 shares in the last quarter. Rathbones Group PLC acquired a new stake in IQVIA in the 3rd quarter valued at $425,000. V Square Quantitative Management LLC bought a new stake in IQVIA during the 3rd quarter worth about $181,000. Mariner LLC boosted its stake in shares of IQVIA by 9.0% during the 3rd quarter. Mariner LLC now owns 14,566 shares of the medical research company’s stock worth $2,866,000 after buying an additional 1,197 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of IQVIA by 1.8% in the 3rd quarter. Northern Trust Corp now owns 1,737,315 shares of the medical research company’s stock valued at $341,817,000 after acquiring an additional 31,413 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.